Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.
GM1 Virtual Community Conference
To register to attend the conference visit https://registration.socio.events/e/gm1
Morquio B, also known as Mucopolysaccharidosis type IV (MPS IV), is a progressive disease mostly impacting the skeleton, caused by mutations in GLB1, the gene that encodes the beta-galactosidase (GLB) enzyme. GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1. In both diseases, these mutations result in the misfolding and subsequent dysfunction of GLB, which leads to toxic substrate accumulation in organs and tissues. Gain is developing allosteric regulators that are designed to decrease toxic substrate accumulation n organs and tissues of patients with Morquio B and GM1 Gangliosidosis in order to potentially provide the first treatment approach for the disease’s neurological symptoms.
About Gain Therapeutics, Inc.
For more information, please visit https://www.gaintherapeutics.com
Investor & Media Contacts:
Gain Therapeutics Media Contact:
ITEXPO #TECHSUPERSHOW Expo Hall Open
#TECHSUPERSHOW Expo Hall Grand Opening
I Robot Run the Warehouse